Showing results (1061-1070 of 1,201) with videos related to
Sort By:
Pageof 121
Advanced Healthcare Materials|December 3, 2022
A 3D Perfusable Platform for In Vitro Culture of Patient Derived XenograftsLindsey K Sablatura, Kristin M Bircsak, Peter Shepherd, et al.Breast Cancer Research and Treatment|March 26, 2017
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancerMuhammad Asaduzzaman, Stephanie Constantinou, Haoxiang Min, et al.Genomics|May 1, 1992
An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophyN J Sharp, J N Kornegay, S D Van Camp, et al.Journal of Neurology|May 16, 2019
Neurological adverse events post allogeneic hematopoietic cell transplantation: major determinants of morbidity and mortalityIoanna Sakellari, Eleni Gavriilaki, Sotirios Papagiannopoulos, et al.Medical Oncology (Northwood, London, England)|December 28, 2019
Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapyFlorence Chamberlain, Elena Cojocaru, Mariana Scaranti, et al.Journal of the American Heart Association|April 26, 2022
Ongoing Exercise Intolerance Following COVID-19: A Magnetic Resonance-Augmented Cardiopulmonary Exercise Test StudyJames T Brown, Anita Saigal, Nina Karia, et al.JBI Evidence Synthesis|July 3, 2023
Barriers and facilitators for adopting healthy lifestyles in breast cancer survivors: a scoping review protocolAo Shi, King Hei Anthony Fong, Carrie Rodomar, et al.Frontiers in Digital Health|February 27, 2025
Leveraging machine learning and rule extraction for enhanced transparency in emergency department length of stay predictionWaqar A Sulaiman, Charithea Stylianides, Andria Nikolaou, et al.Breast Cancer Research and Treatment|January 7, 2018
Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancerMuhammad Asaduzzaman, Stephanie Constantinou, Haoxiang Min, et al.International Journal of Molecular Sciences|November 25, 2023
Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and OutcomesApostolia Papalexandri, Eleni Gavriilaki, Anna Vardi, et al.Pageof 121